Metabolic regulation has been recognized as a powerful principle guiding immune responses. Inflammatory macrophages undergo extensive metabolic rewiring 1 marked by the production of substantial amounts of itaconate, which has recently been described as an immunoregulatory metabolite 2 . Itaconate and its membranepermeable derivative dimethyl itaconate (DI) selectively inhibit a subset of cytokines 2 , including IL-6 and IL-12 but not TNF. The major effects of itaconate on cellular metabolism during macrophage activation have been attributed to the inhibition of succinate dehydrogenase 2,3 , yet this inhibition alone is not sufficient to account for the pronounced immunoregulatory effects observed in the case of DI. Furthermore, the regulatory pathway responsible for such selective effects of itaconate and DI on the inflammatory program has not been defined. Here we show that itaconate and DI induce electrophilic stress, react with glutathione and subsequently induce both Nrf2 (also known as NFE2L2)-dependent and -independent responses. We find that electrophilic stress can selectively regulate secondary, but not primary, transcriptional responses to toll-like receptor stimulation via inhibition of IκBζ protein induction. The regulation of IκBζ is independent of Nrf2, and we identify ATF3 as its key mediator. The inhibitory effect is conserved across species and cell types, and the in vivo administration of DI can ameliorate IL-17-IκBζ-driven skin pathology in a mouse model of psoriasis, highlighting the therapeutic potential of this regulatory pathway. Our results demonstrate that targeting the DI-IκBζ regulatory axis could be an important new strategy for the treatment of IL-17-IκBζ-mediated autoimmune diseases.
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Differential gene expression in our published transcriptional analysis of DI-treated bone marrow-derived macrophages (BMDMs) 2 showed the enrichment of electrophilic and xenobiotic stress response pathways, specifically the upregulation of classical transcriptional markers of a Nrf2-mediated response 4 such as Hmox1, Nqo1 and Gclm (Fig. 1a) . Indeed, Nrf2 protein levels, as well as the protein levels of its classical target genes, increased during 12 hours of treatment with DI (Fig. 1b) . Endogenous itaconate also induced a KEAP1-Nrf2 response, as Nrf2 protein levels upon lipopolysaccharide (LPS) activation were higher in wild-type macrophages than in Irg1 −/− macrophages (Irg1 is also known as Acod1) (Fig. 1c) . Overall, transcriptional signatures of DI treatment matched those of the KEAP1-knockout macrophages 5 (Extended Data Fig. 1a ), indicating the induction of a global electrophilic stress response.
Considering its structure, DI can readily act as an electrophile in Michael reactions (Extended Data Fig. 1b ) and trigger electrophilic stress, which is usually controlled via glutathione (GSH) buffering. For example, covalent conjugation with GSH has been described for fumarate, a metabolite that typically accumulates in cells with mutated fumarate hydratase 6, 7 . Analysis of the cell media from DI-treated macrophages suggested that DI was taken up from the media, and a substantial peak was found with a retention time of 14.4 min and an m/z of 464.1334; this peak increased during incubation with DI and corresponded to the diester of methylsuccinated GSH (DI-GSH) (Fig. 1d , e, Extended Data Fig. 1c, d ). The origin of DI-GSH was confirmed using synthesized 13 C 5 -labelled DI for cell treatment (Extended Data Fig. 1e) . Notably, the reactivity with GSH was also observed for natural itaconate; we detected methylsuccinated GSH (Ita-GSH, Fig. 1d ) in LPS-stimulated macrophages, which correlated with itaconate production and was absent in Irg1 −/− cells (Fig. 1f) . The identities of the DI-GSH and Ita-GSH conjugates were confirmed by comparing their liquid chromatography-mass spectrometry retention times with those of chemically synthesized standards (Extended Data Fig. 1f, g ).
The reactivity of DI led to a substantial decrease in cellular GSH concentration and an associated increase in the generation of reactive oxygen species (Fig. 1g, Extended Data Fig. 1h ). Therefore, we tested a panel of antioxidants (scavengers of reactive oxygen species) by administering them simultaneously with DI. Co-treatment with only N-acetylcysteine (NAC) or cell-permeable GSH (EtGSH) reversed the effect of DI, suggesting that DI acts preferentially by modulating the cellular pool of thiol-containing molecules (Fig. 1h , Extended Data Fig. 1i ). The prototypical electrophile dimethyl fumarate (DMF) also triggered an Nrf2 response and showed selective inhibition of IL-6 ( Fig. 1i, Extended Data Fig. 1j) .
Tnf is induced during the primary transcriptional response to toll-like receptor (TLR) stimulation, whereas Il6 is a product of the secondary transcriptional responses 8 . The major transcription factor that has been reported to selectively regulate secondary transcriptional response to TLR activation is IκBζ, which is encoded by the Nfkbiz gene 9 ( Fig. 2a , Extended Data Fig. 2a, b) . Notably, DI completely abolished the LPS-associated induction of IκBζ protein and inhibited its target genes (including Il12b and Edn1) in both BMDMs and human blood monocytes (Fig. 2b , Extended Data Fig. 2c-g ). This suggested that the observed specificity of action of DI on IL-6 may result from the selective inhibition of the secondary transcriptional response to TLR activation. Indeed, DI did not inhibit IκBα degradation and upstream signalling in response to LPS, nor did it prevent LPS-mediated p65 nuclear translocation (Extended Data Fig. 2h-j) . We next tested whether the NAC-or EtGSH-mediated Letter reSeArCH reversal of the effect of DI on IL-6 was associated with the recovery of IκBζ protein induction. Indeed, co-treatment of BMDMs with DI and NAC (or EtGSH), but not α-tocopherol, restored LPS-mediated IκBζ induction in BMDMs and in human blood monocytes, whereas NAC itself did not increase IL-6 levels in untreated or DI-treated Nfkbiz −/− BMDMs (Fig. 2c , Extended Data Fig. 2k-m) . Consistent with the idea that the primary NF-κB-mediated response is not affected by DI at this concentration range, Nfkbiz mRNA levels were unchanged upon DI treatment, meaning that IκBζ protein induction is affected at the post-transcriptional level (Fig. 2d , e, Extended Data Fig. 3a) .
To understand the regulation of IκBζ protein, we used proteasome inhibitor MG132 and autophagosome-lysosome fusion inhibitor bafilomycin A, but neither rescued IκBζ induction during DI treatment (Extended Data Fig. 3b) . Additionally, the action of DI could not be attributed to the regulation of Nfkbiz 3′ untranslated region (UTR) 10 , as indicated by a GFP reporter assay (Extended Data Fig. 3c ). Finally, cellular stress has been shown to regulate mRNA translation via phosphorylation-driven inactivation of eIF2α 11 . Indeed, we detected a marked increase in macrophage eIF2α phosphorylation in response to DI (Extended Data Fig. 3d ), suggesting that the inhibitory effect of DI on IκBζ protein levels is associated with the regulation of IκBζ 
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translation. However, this suppression was very specific to IκBζ and possibly a few other proteins; DI did not affect protein synthesis globally, as judged by either metabolic labelling of nascent proteins or proteomic profiling of DI-treated macrophages (Extended Data Fig. 3e-h ).
To further understand the effect of electrophilic stress on the IκBζ-mediated inflammatory program, we tested a panel of itaconate derivatives with different electrophilicities and also included DMF (Fig. 2f) . The inhibitory effects of the compounds on IκBζ correlated with their electrophilic strength: DI, DMF and 1-ethyl itaconate (1EI) inhibited IκBζ induction, whereas 4-ethyl itaconate (4EI) did not (Fig. 2g, h ). To decouple the contribution of the feedback GSH synthesis during the electrophilic stress response to these compounds, we tested combinations of itaconate derivatives with buthionine sulfoximine (BSO), a non-electrophilic inhibitor of GSH synthesis, which itself neither inhibits cytokine production nor triggers a Nrf2 response (Extended Data Fig. 4a-c) . BSO enhanced the inhibitory effect of DI on IκBζ-IL-6 (Fig. 2i , Extended Data Fig. 4d ) and unlocked the effect of 4EI on IκBζ-IL-6 (Fig. 2j, Extended Data Fig. 4e) .
We next considered the effects of endogenously produced itaconate, which is a weak electrophile, on the IκBζ-regulatory axis. The temporal dynamics of IκBζ upon LPS activation are very different from those of itaconate: levels of IκBζ reach a maximum at around 1 hour and are already reduced considerably by around 4 hours, whereas itaconate is only induced at around 2-4 hours and plateaus later after LPS stimulation (Fig. 2k ). As such, to address the physiological relevance of endogenous itaconate to IκBζ regulation, we designed an experiment in which both natural itaconate and IκBζ are present in the cells at the same time. Specifically, we have evaluated in vitro macrophage tolerization, when cells are first stimulated with LPS and then rechallenged with LPS at 18 hours. This design ensures that endogenous itaconate is produced in sufficient amounts and LPS restimulation triggers IκBζ induction once again. We observed that, in the presence of BSO, there was a marked difference in IκBζ protein levels upon restimulation between Irg1
−/− and wild-type cells (Fig. 2l , Extended Data Fig. 4f ), confirming the potential regulatory effects of natural itaconate on IκBζ.
We next aimed to identify major regulatory hubs connecting the electrophilic stress to the blockade of IκBζ induction. First, we tested whether Nrf2 is involved in the inhibition of IκBζ synthesis by DI. Nrf2-deficient BMDMs did not alleviate DI-mediated IκBζ and IL-6 inhibition (Fig. 3a, b, Extended Data Fig. 5a ). Similarly, macrophages genetically lacking p62 (also known as SQSTM1) 12 or HO-1 13 did not rescue DI-mediated IκBζ inhibition (Extended Data Fig. 5b-d Letter reSeArCH expressed upon treatment with DI (Extended Data Fig. 5e ). Most of the differentially DI-regulated pathways of the integrated stress response were upregulated (Atf3, Atf4 and Eif2ak3 (also known as Perk)), whereas the interferon (IFN) response pathways (for example, Isg15) were consistently downregulated (Fig. 3c , Extended Data Fig. 5f ). Focusing on ATF3 as a potential candidate 14 , we compared our Nrf2-independent transcriptional signature of DI treatment to the publicly available dataset that profiled wild-type and Atf3 −/− macrophages at their basal states 15 . Notably, we found highly statistically significant overlap between genes regulated by ATF3 and genes regulated by DI (Fig. 3d) , suggesting that the action of DI might be mediated by ATF3. Indeed, the protein ATF3 was upregulated by DI treatment even on an Nrf2 −/− background (Fig. 3e) . Furthermore, Atf3 −/− cells restored IκBζ protein levels upon DI treatment and significantly increased IL-6 production in DI-treated Atf3 −/− cells compared to the wild type (Fig. 3f, g ). In Atf3 −/− macrophages, DI failed to increase eIF2α phosphorylation, even though it still induced an Nrf2 response (Extended Data Fig. 5g, h ). DI-mediated ATF3 expression was efficiently decreased by co-treatment with NAC or EtGSH in both mouse macrophages and human monocytes (Extended Data Fig. 5i-k) . Endogenous itaconate also efficiently induced an ATF3 response: when we compared wildtype and Irg1
−/− BMDMs tolerized in the presence of BSO and then restimulated, ATF3 was induced in wild-type cells but not in Irg1
Notably, IκBζ also has a major role outside the macrophage context: it is induced upon IL-17 treatment of epithelial cells and orchestrates downstream inflammatory responses [16] [17] [18] . Nfkbiz polymorphisms have been associated with several immune-related conditions, including psoriasis 19 .
As such, we first tested the in vitro effect of DI pretreatment on IκBζ induction in IL-17A-stimulated primary keratinocytes. The induction of IκBζ was inhibited by DI in primary mouse and human keratinocytes (Fig. 4a , b, Extended Data Fig. 6 ). To further examine the inhibitory effect of DI on IκBζ induction by IL-17, we analysed expression of the well-characterized IκBζ target genes Defb4, S100a7a, Lcn2 and S100a9 in mouse and human keratinocytes. As expected, the expression of these genes was downregulated by DI in correlation with IκBζ protein levels (Fig. 4c, d ). These data suggest that DI can also modulate the induction of IκBζ in several immune contexts.
We next explored the ability of DI to interfere with IκBζ signalling in vivo. We used a mouse model of psoriasis induced by the TLR7/8 agonist imiquimod (IMQ). In this model, skin inflammation is induced by topical application of IMQ cream onto the ears of mice to induce a psoriasis-like pathology resembling the human disease. Daily topical application of IMQ to the skin of the ear for seven days led to considerable scaling and oedema of the skin in control animals, whereas mice treated with DI in addition to IMQ showed no detectable skin changes (Fig. 4e-g ). Similarly, quantitative analysis of ear-skin-derived mRNA showed significant induction of the IκBζ target genes Defb4, S100a9, S100a7a and Lcn2 after IMQ application, whereas their expression was markedly reduced in the skin of mice treated with DI (Fig. 4h) . Daily DI administration did not affect succinate dehydrogenase activity in the heart and the liver considerably (Extended Data Fig. 7) , suggesting a favourable safety profile. These data demonstrate that DI can act as an IκBζ inhibitor in vivo and could provide a targeted approach for treating various autoimmune conditions.
Online content
Any Methods, including any statements of data availability and Nature Research reporting summaries, along with any additional references and Source Data files, are available in the online version of the paper at https://doi.org/10.1038/s41586-018-0052-z. 22 and control C57BL/6 wild-type mice were provided by T.H.. Mice used for the study were 6-12 weeks old. Unless stated otherwise, female mice were used. Bone marrow-derived macrophages and mouse cell cultures. BMDMs were prepared from 6-to 12-week-old mice as described 1 and cultured in RMPI-1640 medium supplemented with 10% fetal bovine serum (FBS), 2 mM l-glutamine and 100 U ml −1 penicillin-streptomycin and mouse recombinant macrophage colony stimulating factor (20 ng ml ) and IFNγ (50 ng ml −1 , Peprotech). In some experiments cells were treated with α-tocopherol (10 µM, Sigma), MitoTEMPO (500 µM, Sigma), N-acetylcysteine (1 mM, Sigma), the ethylester of GSH (EtGSH; 1 mM, Santa Cruz Biotechnology) or buthionene sulfoximine (BSO; 500 µM, Sigma) alone or in combination with DI for 12 h. In some experiments BMDMs were treated with DI for 12 h and bafilomycin A (100 nM, Sigma) or MG132 (10 µM, Selleckchem) were added 30 min before subsequent LPS stimulation.
Additional information
In tolerization experiments, cells were stimulated with LPS (100 ng ml
) for 18 h then washed with PBS at 37 °C and restimulated with LPS (100 ng ml ) for 1 h. In some samples, BSO (500 µM) was present during the first stimulation.
The BV2 microglial cell line was a gift from H. Virgin. BV2 cells were maintained in DMEM medium supplemented with 10% FBS, 2 mM l-glutamine, 1 mM sodium pyruvate and 100 U ml −1 penicillin-streptomycin. BV2 responsiveness to TLR stimulation was tested and cells were not tested for mycoplasma contamination. RNA sequencing analysis. mRNA was extracted with oligodT beads (Invitrogen), and libraries were prepared and quantified as described previously 23 . All RNA-seq experiments were performed in n = 2 independent cultures. Raw and processed data were deposited in the Gene Expression Omnibus. Pre-ranked gene set enrichment analysis (GSEA) was performed using the fgsea R package 24 . For the analysis of wild-type and Nrf2 −/− BMDMs, genes were ranked according to signal-to-noise statistics; only the top 10,000 genes ordered by mean expression were considered. MSigDB C2 and H gene set collections were used. For the analysis of KEAP1 conditional knockout (KpCKO) (GSE71263) 5 and Atf3 −/− (GSE61055) 15 datasets, differential expression analysis was carried out using the limma package 25 , genes were ranked by the corresponding test statistics and P values were calculated using the GSEA method in the fgsea R package 24 with 200,000 gene-set permutations. Heat maps were generated using the Phantasus online service (https://artyomovlab. wustl.edu/phantasus/). Western blots. Cells were lysed in RIPA lysis buffer system (Santa Cruz Biotechnology) and heat-denatured at 95 °C for 5 min in reducing sample buffer (Bio-Rad). Proteins were separated on 4-20% polyacrylamide gradient gels (BioRad) and transferred onto PVDF membranes (0.45 µm pore size, Millipore). Non-specific binding was blocked with 5% skim milk (or 5% BSA when phosphoproteins were analysed), and membranes were probed with primary antibodies specific to Nrf2 (#12721), HO-1 (#70081), IκBζ (mouse-specific, #93726), IκBζ (#9244), ATF3 (#D2Y5W), IRAK1 (#4504; sensitivity of IRAK1 detection diminishes upon IRAK1 K63 ubiquitination 26 ), phospho-IKK (Ser176/180, #2697), p62 (also known as SQSTM1) (#5114), phospho-eIF2α (Ser51, #9721), eIF2α (#5324) from Cell Signaling; glyceraldehyde 3-phosphate dehydrogenase (GAPDH; sc-25778), IκBα (sc-1643), ATF3 (sc-188), succinate dehydrogenase complex, subunit A (SDHA; sc-166909) from Santa Cruz Biotechnology; NQO1 (ab28947) from Abcam, followed by incubation with anti-rabbit-HRP (1:10,000; sc-2030) or anti-mouse-HRP (1:10,000; sc-2031) from Santa Cruz Biotechnology and Clarity Western ECL substrate (Bio-Rad). Membranes were exposed to X-ray films (Research Products International) and developed using an SRX-101A film processor (Konica Minolta). GAPDH run on the same blot was used as a loading control. After the scanning of original films, the image brightness of some blots was adjusted and bands were cropped using ImageJ 27, 28 . Densitometry was performed using ImageJ. For gel source data (unadjusted and uncropped images containing molecular size marker), see Supplementary Fig. 1 . DI detection with gas chromatography-mass spectrometry (GC-MS). For DI measurement, medium was collected from cells at various time points during incubation with 250 µM DI, and placed on ice. An equal volume of ethyl acetate (Sigma) was added and the samples were vortexed at 4 °C for 1 min. After centrifugation at 14,000g for 2 min at 4 °C, the organic phase was collected and approximately 20-30 mg of sodium sulfate (Sigma) was added. The samples were vortexed before analysis. Analysis was performed using a TRACE 1300 GC equipped with a 30-m DB-35MS capillary column connected to a Thermo TSQ Quantum MS operating under electron impact ionization at 70 eV. 1 µl of sample was injected in splitless mode at 270 °C, using helium as the carrier gas at a flow rate of 1 ml min −1
. The GC oven temperature was held at 100 °C for 3 min and increased to 240 °C at 3.5° min (21,694g for 10 min at 4 °C), the supernatant was collected and transferred to another 96-well plate, and the solvent was evaporated under reduced pressure using EZ-2 (Genevac). Before injection, dried extracts were reconstituted, or medium was diluted (1:20) in LC-MS grade water. The extracted samples were analysed by high-resolution accurate mass lLC-MS. LC separation was achieved by reverse-phase ion-pairing chromatography. The system consisted of a Vanquish (Thermo Fisher Scientific) pumping system, coupled to an autosampler and degasser. Chromatographic separation was performed using a Synergy Hydro-RP column (100 mm × 2 mm, 2.5 µm particle size, Phenomenex). The elution gradient involved a binary solvent system as described previously 29 . Accurate mass data were acquired using a Q Exactive Orbitrap mass spectrometer (Thermo Fisher Scientific), which was equipped with a heated electrospray ionization source operated in negative electrospray mode. Ionization source working parameters were optimized; the heater temperature was set to 300 °C, ion spray voltage was set to 3,500 V. An m/z scan range from 70 to 700 was chosen and the resolution was set at 70,000. The automatic gain control target was set at 1e6 and the maximum injection time was 250 ms. Instrument control and acquisition was achieved using Xcalibur 2.2 software (Thermo Fisher Scientific). All data analysis was conducted using El-MAVEN software 30 .
Synthesis of DI-GSH conjugate (N5-(1-((carboxymethyl)amino)-3-((4-methoxy-2-(methoxycarbonyl)-4-oxobutyl)thio)-1-oxopropan-2-yl)glutamine).
To a vial charged with dimethyl 2-methylenesuccinate (0.158 g, 1.0 mmol) was added ethanol (1.000 ml) and triethylamine (0.167 ml, 1.200 mmol) and the mixture was cooled in an ice-water bath before the addition of GSH (0.369 g, 1.200 mmol). The resulting suspension was stirred overnight and allowed to slowly warm to room temperature (ice melt) affording a light yellow solution. The mixture was dried under reduced pressure and purified by RP-HPLC as follows: Agilent automated purification system with single quad MS and DAD; Waters AcQuity UPLC I-Class with QDa and UV; XSelect CSH Prep C18 OBD 5 µm 19 × 100 column. Solvents A and B were water with 0.1% formic acid, and acetonitrile, respectively. The method time was 10 min, with a gradient from 10% B to 40% B over 5 min. Samples were loaded at 10% B. The flow rate during the loading was 25 ml min −1 and it was raised to 40 ml min 
Synthesis of Ita-GSH conjugate (2-(((2-(4-amino-4-carboxybutanamido)-3-((carboxymethyl)amino)-3-oxopropyl)thio)methyl)succinic acid).
To a vial charged with 2-methylenesuccinic acid (itaconic acid; 0.021 g, 0.163 mmol) was added water (0.651 ml) and GSH (0.05 g, 0.163 mmol). The resulting suspension was heated at 37 °C overnight, affording a pale yellow solution, which was directly purified by RP-HPLC as follows: XSelect Prep C18 5 µm 19 × 100 column. Solvents A and B were water with 0.1% formic acid, and acetonitrile, respectively. The method time was 10 min with a gradient from 5% B to 10% B over 5 min. Samples were loaded at 5% B. The flow rate during the loading and the separation was NaMoO 4 , 0.05 g l −1 H 3 BO 3 . The bacteria were allowed to grow for 6 days until the OD 420 reached 1.9-2.1. The cells were pelleted by centrifugation for 30 min at 14,000g and 4 °C. The supernatant was collected and lyophilized to afford a white powder (3.78 g). The powder was re-dissolved in distilled H 2 O (10 ml) and the pH reduced to 2 using concentrated HCl (around 0.5 ml). 13 C-labelled itaconate was extracted into ethyl acetate (4 × 15 ml). The combined organic layers were dried over anhydrous Na 2 SO 4 and concentrated in vacuo to afford + calcd. 158.0326, found 158.0328.
The reactant 13 C-itaconic acid (0.10 g, 9.5 mmol) was dissolved in methanol (1 ml). To this solution was added one drop of concentrated H 2 SO 4 and the mixture was refluxed overnight (16 h). The reaction was quenched with saturated NaHCO 3 (1 ml), then extracted into dichloromethane (2 × 2 ml). The combined organic layers were dried over anhydrous Na 2 SO 4 to afford a brown liquid. Yield: 97 mg, 80%. ) for 1 h, or (3) only treated with DI (250 µM) for 12 h, or (4) treated with neither DI nor LPS. Cells were then washed three times with PBS and lysed in 200 µl of urea buffer (8 M urea, 75 mM NaCl, 50 mM Tris pH 8.0, 1 mM EDTA). Lysates were then cleared by centrifugation at 20,000g and protein concentrations were determined by BCA assay (Pierce). 15 µg of total protein per sample were processed further. Disulfide bonds were reduced with 5 mM dithiothreitol and cysteines were subsequently alkylated with 10 mM iodoacetamide. Samples were diluted 1:4 with 50 mM Tris-HCl (pH 8.0) and sequencing grade modified trypsin (Promega) was added in an enzyme-to-substrate ratio of 1:50. After 16 h of digestion, samples were acidified with 1% formic acid (final concentration). Tryptic peptides were desalted on C18 StageTips 32 and evaporated to dryness in a vacuum concentrator. Desalted peptides were labelled with the TMT10plex mass tag labelling reagent according to the manufacturer's instructions (Thermo Scientific) with small modifications. In brief, 0.2 units of TMT10plex reagent was used per 15 µg of sample. Peptides were dissolved in 30 µl of 50 mM HEPES pH 8.5 solution and the TMT10plex reagent was added in 12.3 µl of MeCN. After 1 h incubation the reaction was stopped with 2.5 µl 5% hydroxylamine for 15 min at 25 °C. Differentially labelled peptides were mixed for each replicate and subsequently desalted on C18 StageTips 32 and evaporated to dryness in a vacuum concentrator. The peptide mixtures were fractionated by strong cation exchange (SCX) using StageTips as previously described 32 with slight modifications. In brief, one StageTip was prepared per sample by 3 SCX discs (3 M, cat. no. 2251) topped with 2 C18 discs (3 M, cat. no. 2215). The packed StageTips were first washed with 100 µl methanol and then with 100 µl 80% acetonitrile and 0.2% formic acid. Afterwards they were equilibrated by 100 µl 0.2% formic acid and the sample was loaded onto the discs. The sample was transeluted from the C18 discs to the SCX discs by applying 100 µl 80% acetonitrile; 0.2% formic acid, which was followed by three stepwise elutions and collections of the peptide mix from the SCX discs. The first fraction was eluted with 50 µl of 50 mM NH 4 AcO, 20% MeCN (pH ~7.2); the second with 50 µl 50 mM NH 4 HCO 3 , 20% MeCN (pH ~8.5) and the third with 50 µl 0.1% NH 4 OH, 20% MeCN (pH ~9.5). 200 µl of 0.2% acetic acid was added to each of the three fractions and they were subsequently desalted on C18 StageTips as previously described 32 and evaporated to dryness in a vacuum concentrator. Peptides were reconstituted in 10 µl 0.2% formic acid. Both the unfractionated samples and the fractionated, less complex samples were then analysed by LC-MS/ MS on a Q Exactive HF as previously described 33, 34 . In brief, around 1 µg of total peptides were analysed on an Eksigent nanoLC-415 HPLC system (Sciex) coupled via a 25-cm C18 column (inner diameter of 100 µm, packed in-house with 2.4 µm ReproSil-Pur C18-AQ medium, Dr. Maisch GmbH) to a benchtop Orbitrap Q Exactive HF mass spectrometer (Thermo Fisher Scientific). Peptides were separated at a flow rate of 200 nl min −1 with a linear 206-min gradient from 2% to 25% solvent B (100% acetonitrile, 0.1% formic acid), followed by a linear 5-min gradient from 25 to 85% solvent B. Each sample was run for 270 min, including sample loading and column equilibration times. Data were acquired in data-dependent mode using Xcalibur 2.8 software. MS1 spectra were measured with a resolution of 60,000, an automatic gain control target of 3e6 and a mass range from 375 to 2000 m/z. Up to 15 MS2 spectra per duty cycle were triggered at a resolution of 60,000, an automatic gain control target of 2e5, an isolation window of 1.6 m/z and a normalized collision energy of 36.
All raw data were analysed with MaxQuant software 35 version 1.6.0.16 using a UniProt Mus musculus database (downloaded on 16 May 2017), and MS/MS searches were performed with the following parameters: The five mass spec runs were grouped together. TMT11plex labelling on the MS2 level, oxidation of methionine, deamidation of asparagine and protein N-terminal acetylation as variable modifications; carbamidomethylation as fixed modification; Trypsin/P as the digestion enzyme; precursor ion mass tolerances of 20 p.p.m. for the first search (used for nonlinear mass re-calibration) and 4.5 p.p.m. for the main search, and a fragment ion mass tolerance of 20 p.p.m. For identification, we applied a maximum false discovery rate of 1% separately on protein and peptide level. We required one or more unique/razor peptides for protein identification and a ratio count for each of the 10 TMT channels. This gave us a total of 4,123 quantified protein groups.
Finally, we normalized the MaxQuant-generated corrected TMT intensities such that at each condition or time point the corrected TMT intensity values added up to exactly 1,000,000, therefore each protein group value can be regarded as a normalized microshare (we did this separately for each TMT channel for all proteins that made our filter cutoff in all the TMT channels. After that we added a pseudocount of 1 to each intensity value in order to account for the noise level and make our fold-change calls more robust for small intensity values. Finally, we log 2 -transformed all values and took the average of the log 2 values for all replicates per condition (if replicate samples were present). Metabolic labelling of nascent protein synthesis with click chemistry. BMDMs were grown in 12-well plates, 10 6 cells per well and treated with DI (250 µM) for 10 h. The cells were then washed three times with methionine-deficient media and incubated for 1 h without methionine in the presence of 200 µM DI. After that, l-azidohomoalanine (Click-iT AHA, C10102, Invitrogen) was added directly to cell media to a final concentration of 50 µM. The cells were then stimulated with LPS for 1 h. In some samples, cells were treated with puromycin (5 µg ml
) for 2 h before LPS stimulation to block translation. Cells were lysed in 100 µl of lysis buffer (50 mM Tris-HCl, pH 8, 1% SDS) supplemented with protease inhibitor cocktail, phenylmethylsulfonyl fluoride and Na 3 VO 4 (Santa Cruz Biotechnology). Lysates were incubated on ice for 30 min, sonicated and cleared by centrifugation at 13,000g for 5 min at 4 °C. Total protein concentration was determined using an RC/DC Protein Assay (Bio-Rad). 30 µg of protein was used for the downstream reaction with 40 nM biotin-alkyne (B10185, Invitrogen) and the reaction was carried out in Click-iT Protein Reaction Buffer Kit (C10276, Invitrogen) according to the manufacturer's protocol. Proteins were separated on 4-20% polyacrylamide gradient gels (Bio-Rad) and biotinylated proteins were detected by western blot with a streptavidin-HRP conjugate (1:1000, #554066, BD Pharmingen). The membrane was stripped using 0.2 M NaOH and reprobed to detect IκBζ (see 'Western blots'). Glutathione measurement. The total GSH concentration in cells was determined by a GSH/GSSH Ratio Detection Assay Kit (Abcam) according to the manufacturer's protocol. In brief, 10 6 BMDMs were lysed in 100 µl of 0.5% NP-40 in PBS, pH 6. Samples were deproteinized using trichloroacetic acid and neutralized by the addition of 1 M NaHCO 3 to achieve pH values of 4-6. Collected extracts were diluted with the supplied assay buffer and used directly for GSH measurement. Cytokine detection. Cytokines in cell supernatants were analysed using DuoSet ELISA kits according to the manufacturer's protocol (R&D Systems). The supernatants from BMDMs were diluted 1:4, those from human blood monocytes were diluted 1:3. RNA isolation and quantitative real-time PCR. RNA from cultured cells was isolated using a Total RNA I kit (Omega). RNA from the skin of mouse ears was extracted using an RNeasy mini kit (Qiagen) after tissue disruption with sterile zirconium beads on a MagNA Lyser (Roche). Isolated RNA was reverse-transcribed using AffinityScript Multi-Temp reverse transcriptase (Agilent Technologies) according to the manufacturer's protocol. Reactions were performed in 96-well plates using a SYBR Green PCR Master mix (Thermo Fisher Scientific) using a LightCycler 96 or LightCycler 480 (Roche Diagnostics). All assays were performed at least in duplicate, and reaction mixtures in 20-µl volumes (96-plate) or 10-µl volumes (384-plate) were processed under the following cycling conditions: initial 10 min denaturation at 95 °C, followed by 40 cycles at 95 °C for 10 s, 60 °C for 1 min. Threshold cycle values for each sample were determined by automated threshold analysis. Expression levels of all mRNAs were normalized to reference gene Actb in BMDMs or to Rpl19 in mouse keratinocytes and tissue samples; to ACTB in human blood monocytes or RPLP0 in human keratinocytes. The relative increase in the expression level of a gene was normalized to the level of expression in unstimulated control cells in each experiment. Primer pairs used are listed in Supplementary  Table 1 , 25 kDa, linear form, Polysciences) was used. The mixture was incubated at room temperature for 20 min and added to HEK-293T cells (ATCC) cultured in DMEM supplemented with 10% FBS, 2 mM l-glutamine and 100 U ml −1 penicillin-streptomycin in a 150 cm 2 tissue-culture flask. After 48 h, virus-containing medium was filtered through cellulose acetate filters (45 µm pore-size) and used directly for BV2 transduction in the presence of polybrene (8 µg ml
, Millipore). The next day, the medium was replaced and two days after this the cells were selected with puromycin at 5 µg ml ) and the percentage of negative cells was plotted. Cells were acquired on CantoII or LSRII flow cytometers (Becton Dickinson), and data were analysed with FlowJo v.9.5.2 software (Tree Star). For the gating strategy, see Supplementary Fig. 2 . Confocal microscopy. BMDMs were seeded at 8-well multitest microscopy slides (MP Biomedicals). Cells were treated with DI (250 µM, 12 h) and then stimulated with LPS (100 ng ml −1 , 30 min). The cells were fixed with 3% paraformaldehyde in PBS for 30 min and permeabilized with 0.1% Triton X-100 in PBS for 15 min. After washing with PBS, samples were blocked with 1% BSA for 15 min and subsequently labelled with p65-specific antibody (1:50, #8242, Cell Signaling), followed by AF568-conjugated anti-rabbit secondary antibody (1:500, #A11011, Thermo Fisher Scientific) in PBS containing 1% BSA. After labelling, the cells were washed with PBS and mounted in 50% (w/v) glycerol in PBS, pH 8.5 containing 4′,6-diamidino-2-phenylindole (DAPI; 1 µg ml −1 , Sigma) to label nuclei. Images of random fields of view were acquired using a Leica DMi8 confocal microscope (Leica Microsystems) equipped with a HC PL APO 40×/1.3 NA oil immersion objective and exported with LAS AF Lite software (Leica). Human blood monocytes isolation and treatment. Blood from healthy donors was acquired from leukoreduction chambers supplied by the Mississippi Valley Regional Blood Center. Peripheral blood mononuclear cells from buffy coats were recovered from the Ficoll interface after a 400g centrifugation for 30 min. Monocytes were isolated by adherence on a cell-culture dish for 1 h at 37 °C and 5% CO 2 in RPMI containing 1% human serum albumin (Albutein). After extensive washes to remove non-adherent cells, monocytes (≥95% purity) were collected, counted and 5 × 10 5 cells were plated per well in 24-well plates. The cells were treated with DI (125 µM unless stated otherwise) for 12 h and stimulated with LPS (100 ng ml ) for 1 h or as indicated. In some experiments cells were treated with DI in the presence of EtGSH (1 mM, Santa Cruz Biotechnology). Primary mouse and human keratinocytes. Primary keratinocytes were isolated from C57BL/6 wild-type newborn mice or human foreskins as previously described 38 . 2 × 10 5 cells in 1 ml of KFSM media (Gibco 10725-018) (Ca 2+ concentrations of 0.05 mM (mouse) and 0.09 mM (human)) were plated in 12-well tissue culture plates. After 2-3 days of cultivation, mouse or human cells were treated with DI for 12 h and then stimulated with mouse recombinant IL-17A (100 ng ml −1 ; cat. no. 421-ML, R&D Systems) or human recombinant IL-17A (100 ng ml −1 ; 7955-IL, R&D Systems) for 4 h or as indicated. IMQ-induced psoriasis. To induce experimental psoriasis 39 , imiquimod (IMQ; imiquimod cream 5%, Perrigo. Co.) was applied daily to mice on both ears (~5 mg per ear) for 7 days. For the DI-treated mice, DI was administered via the intraperitoneal route at 20 mg in 500 µl sterile PBS per mouse one day before IMQ application and daily thereafter for seven days. After seven days, mice were euthanized and ears were used for RNA extraction or histological analysis by performing haematoxylin and eosin staining on 7-µm thick sections after paraffin embedding. The average ear thickness in each sample was quantified from images obtained at identical settings using ImageJ 27, 28 . Thickness at five equidistant places in each image was quantified and the mean of these values was used to represent results in each mouse. SDH activity in mouse heart and liver. DI was administered to mice via the intraperitoneal route at 20 mg in 500 µl sterile PBS per mouse, either once per day for a total length of four days (DI daily) or every 2 h, three times in total (DI overdose). For the daily DI administration, the last injection was 6 h before the tissue collection, and in the DI overdose protocol the last injection was 2 h before collection. Mice were euthanized and heart (~50 mg) and liver tissue (~200 mg) were collected, washed in PBS and mitochondria were isolated with Mitochondria Isolation Kit for Tissue (#89801, Thermo Scientific) according to the manufacturer's protocol. For the analysis of mitochondrial purity, cytoplasmic and mitochondrial fractions were diluted with reducing sample buffer and analysed by western blot for the presence of SDH and GAPDH (see 'Western blots'). SDH activity in isolated mitochondria was analysed using an SDH Activity Colorimetric Kit (#MAK197, Sigma). Isolated mitochondria were directly resuspended in SDH assay buffer. In parallel, protein concentration in each sample was determined using RC/DC Protein Assay (Bio-Rad) and activity was normalized to protein concentration. Statistical analysis. Unless stated otherwise, standard statistical analyses were performed using MS Excel or GraphPad Prism 7. The type and number of replicates and the statistical tests used are described in the figure legends. Exact P values are shown where determined. Individual data points are shown, and the mean ± s.e.m. is reported for analyses where n > 2, only the mean is reported where n ≤ 2. Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper. Data availability. The raw and processed RNA-seq data have been deposited in the Gene Expression Omnibus with accession numbers GSE102190 and GSE110749. The original mass spectra may be downloaded from MassIVE (http://massive.ucsd.edu) using the identifier MSV000082101. Source data for the graphical representations found in all figures and Extended Data figures are provided. Source data for western blots (uncropped and unprocessed scans with size marker indications) are presented in Supplementary Fig. 1 . All other data that support the findings of this study are available from the corresponding author upon reasonable request. Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
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Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.
Experimental design 1 . Sample size Describe how sample size was determined.
No power calculations were performed. Sample size was chosen according to the experiment type and based on what is standard practice in the field.
Data exclusions
Describe any data exclusions.
No data were excluded.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
All data were successfully replicated. Most of the experiments were independently replicated 3 times unless indicated otherwise in the figure legends.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
No randomization was performed since this was not relevant to the study. Age and sex matched animals for the in vivo experiments were randomly assigned to the experimental groups.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
No blinding was performed since none of the analyses reported involved procedures that could be influenced by investigator bias. Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
